Ann: Non-Deal Roadshow Presentation March-April 2019, page-6

First 6 Last

Share
Profile

Follow
snoopyboy2000

76 Posts.

2

27/03/19

14:05

Post #: 37900985
Share

Originally posted by ajostu: ↑

I suppose the key modifier is the phrase “post approval”.
However remember the ann from Oct last year which said that illumet was (at that point) “now available commercially”. So this is an update that seems to imply that this is No Joke. They are not giving the stuff away.

One thing we don’t know is what costs of manufacture are so that will be an interesting thing to,look out for in future quarterlies.

So let’s look at where things stand.

Firstly they’ve sorted out a production pipeline for 20k units per year. Getting your supply chain right is a big deal and for me a very important positive, having been invested previously with companies where timelines for this blew out.
Secondly they’ve made the point that the NDA is being submitted after careful consultation with the FDA.
I would hope that means the FDA is happy with the 250 person EU trial database and that there aren’t funny issues with that information (a la the older non-placeboed FTT trial)
Thirdly the naive statistic is that 80% of NDAs get up. So as far as playing the odds you’d have to say worth a punt. And this is only one of their products.

They’ve not been an HC ramper’s darling which is also a good thing for me.

Expand

they are selling about 1000 kits a month for circa usd 650, can scale that up to 2,000 kits a month

once approved they get FDA they can charge around usd 4,000 a kit

so yes they are currently making rev

Originally posted by ajostu: ↑

I suppose the key modifier is the phrase “post approval”.
However remember the ann from Oct last year which said that illumet was (at that point) “now available commercially”. So this is an update that seems to imply that this is No Joke. They are not giving the stuff away.

One thing we don’t know is what costs of manufacture are so that will be an interesting thing to,look out for in future quarterlies.

So let’s look at where things stand.

Firstly they’ve sorted out a production pipeline for 20k units per year. Getting your supply chain right is a big deal and for me a very important positive, having been invested previously with companies where timelines for this blew out.
Secondly they’ve made the point that the NDA is being submitted after careful consultation with the FDA.
I would hope that means the FDA is happy with the 250 person EU trial database and that there aren’t funny issues with that information (a la the older non-placeboed FTT trial)
Thirdly the naive statistic is that 80% of NDAs get up. So as far as playing the odds you’d have to say worth a punt. And this is only one of their products.

They’ve not been an HC ramper’s darling which is also a good thing for me.

Expand

TLX Price at posting: 75.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

FNX

Aussie Broadband set to kick off share buyback starting Q1 CY2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

There are more pages in this discussion • 3 more messages in this thread...

First 6 Last

Add TLX (ASX) to my watchlist

(20min delay)
Last $23.37		Change -0.230(0.97%)		Mkt cap ! $6.278B

Open	High	Low	Value	Volume
$23.50	$23.64	$23.25	$7.736M	330.4K

Buyers (Bids)

No.	Vol.	Price($)
7	512	$23.36

Sellers (Offers)

Price($)	Vol.	No.
$23.37	213	3

View Market Depth

No.	Vol.	Price($)
2	11929	18.170
2	6914	18.160
2	1237	18.150
1	2114	18.140
1	4556	18.130

Price($)	Vol.	No.
18.320	1237	2
18.330	4556	1
18.340	1500	1
18.350	1000	1
18.360	4778	2

Last trade - 15.00pm 27/11/2024 (20 minute delay)

TLX (ASX) Chart

Ann: Non-Deal Roadshow Presentation March-April 2019, page-6

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Aussie Broadband set to kick off share buyback starting Q1 CY2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Buyers (Bids)

Sellers (Offers)